{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'The patient has stable performance status', 'The patient does not have rapid progression of disease', 'The patient has not experienced adverse events that would require permanent', 'discontinuation of cemiplimab', 'The patient provides written informed consent prior to resuming treatment by signing', 'the current version of the ICF (eg, the patient repeats the written informed consent that', 'was done prior to initial study enrollment).', 'It is understood that, if there is further progression after resumption of treatment (>30%', 'increase in tumor burden from the time of initial progressive disease by RECIST', 'criteria; this includes an increase in the sum of all target lesions and/or the development', 'of new lesions), that cemiplimab will be discontinued.', '8.7.', 'Management of Acute Reactions', '8.7.1.', 'Acute Infusion Reactions', 'Acute infusion reactions are defined as any AE that occurs during the infusion or within 2 hours', 'after the infusion is completed. Emergency equipment and medication for the treatment of infusion', 'reactions must be available for immediate use. All infusion reactions must be reported as AEs', '(as defined in Section 9.4.1) and graded using the grading scales as instructed in Section 9.5.1.', 'In the event of an infusion reaction of grade 3 or greater severity during or directly following', 'cemiplimab infusion, dosing should be stopped and the patient must be permanently discontinued', 'from cemiplimab treatment.', 'To assist investigators in identifying cemiplimab-related infusion reactions, the following case', 'definition is provided:', 'Typical symptoms may include fever, chills, rigors, skin flushing, dyspnea, back pain,', 'abdominal pain, and nausea', 'Infusion reactions usually occur either during the infusion or within 2 hours after the', 'infusion is completed', 'Vital signs may be notable for hypotension and/or tachycardia', \"The investigator's clinical judgment may include other factors when evaluating a possible\", 'cemiplimab-related infusion reaction. For example, rarely, an infusion reaction may occur up to', '24 hours after initiation of the infusion.', 'Case report forms must capture start and stop time of the event, signs and symptoms, and', 'management interventions (medications, interruption of infusion, rate reduction).', 'Patients who experience grade >3 acute infusion reactions to IC chemotherapy should discontinue', 'treatment.', 'Regeneron Pharmaceuticals, Inc.', 'Page 83 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '8.7.1.1.', 'Interruption of the Infusion', 'The infusion should be interrupted if any of the following AEs are observed:', 'cough', 'rigors/chills', 'rash, pruritus (itching)', 'urticaria (hives, welts, wheals)', 'diaphoresis (sweating)', 'hypotension', 'dyspnea (shortness of breath)', 'vomiting', 'flushing', 'The reaction(s) should be treated symptomatically, and the infusion may be restarted at 50% of the', 'original rate.', 'If investigators feel there is a medical need for treatment or discontinuation of the infusion other', 'than described above, they should use clinical judgment to provide the appropriate response', 'according to typical clinical practice.', 'For patients who experience infusion-related hypersensitivity reactions that are less than grade 3', 'and who plan to continue treatment, premedication will be required for re-treatment.', 'For grade 1 symptoms (mild reaction; infusion interruption not indicated; intervention not', 'indicated), the following prophylactic medications are recommended for future infusions:', 'diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamol 325 mg to 1000 mg at', 'least 30 minutes prior to subsequent cemiplimab infusions.', 'For grade 2 symptoms (moderate reaction that requires therapy or infusion interruption, but for', 'which symptoms resolve promptly with appropriate treatment such as antihistamines, nonsteroidal', 'anti-inflammatory drugs, narcotics, corticosteroids, and/or IV fluids; prophylactic medications', 'indicated 24 hours), the following prophylactic medications are recommended for future', 'infusions: diphenhydramine 50 mg (or equivalent) and/or acetaminophen/paracetamo 325 mg to', '1000 mg at least 30 minutes prior to subsequent cemiplimab infusions. If necessary,', 'corticosteroids (up to 25 mg of hydrocortisone or equivalent) may be used.', '8.7.1.2.', 'Termination of the Infusion', 'The infusion should be terminated and NOT restarted if any of the following AEs occur:', 'anaphylaxis', 'laryngeal/pharyngeal edema', 'severe bronchospasm', 'chest pain', 'Regeneron Pharmaceuticals, Inc.', 'Page 84 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}